01228

1.5804.53%
QX

Qun Xue

Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board

Dr. Qun Xue, Ph.D., M.B.A., also known as James, has served as Chairman of the Board and Chief Executive Officer at CANbridge Pharmaceuticals Inc. since January 2018 and as an executive Director on June 21, 2021 and serves as Strategic Advisory Board. Dr. Xue is the founder of CANbridge Pharmaceuticals Inc. He is Founder, Chairman of the Board and Chief Executive Officer of Canbridge Limited since January 2018 and serves as its Member of Strategic Advisory Board. Dr. Xue serves as Executive Director of Canbridge Limited since June 21, 2021. He has been actively involved in the business, strategy and operational management of our Group since its establishment. Dr. Xue has over 22 years of experience in medical and pharmaceutical companies. He serves as a Founder, Chairman, CEO & Member of Strategic Advisory Board at CANbridge Life Sciences Ltd. Dr. Xue began his career as a scientist at Kosan Biosciences, Inc. from May 1998 to August 2000,where he dedicated himself to research in bioengineering. In 2002, Dr. Xue joined GenzymeCorporation, where he served in various positions with increasing responsibilities including,among others, the general manager of Genzyme China and senior director of business excellence, and accumulated extensive management experience there until 2011. Since June 2012, Dr. Xue has served as venture partner at Tullis Health Investors where he was principally responsible for providing advice on portfolio company investments and maintaining and enhancing company’s brand and market position. Dr. Xue is deputy director general of the China Alliance for Rare Disease (???????), deputy director of the Shanghai Foundation for Rare Disease. He has been the vice chair of the R&D committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) since May 2016 and a member of the Leadership Council of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School since August 2017. Dr. Xue has also been a member of BayHelix Group, a non-profit organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry and a mentor of the Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines. Dr. Xue obtained his Bachelor of Science degree in pharmaceutical chemistry from Peking University School of Pharmacy in July 1992. He further obtained his Ph.D. in bioorganic chemistry from Brown University in April 1997. In addition, Dr. Xue received his postdoctoral degree in pharmaceutical chemistry and biochemistry from University of California in April 1998 and his Master of Business Administration from Darden School of Business, University of Virginia in May 2002.

Positions